使用杜匹单抗和 JAK 抑制剂控制表皮松解性牛皮癣瘙痒症的实际经验。

Q3 Medicine

Skin health and disease Pub Date : 2024-08-19 eCollection Date: 2024-10-01 DOI:10.1002/ski2.445

Ping-Chen Hou, Wilson Aala, Wei-Ting Tu, John A McGrath, Chao-Kai Hsu

{"title":"使用杜匹单抗和 JAK 抑制剂控制表皮松解性牛皮癣瘙痒症的实际经验。","authors":"Ping-Chen Hou, Wilson Aala, Wei-Ting Tu, John A McGrath, Chao-Kai Hsu","doi":"10.1002/ski2.445","DOIUrl":null,"url":null,"abstract":"Epidermolysis bullosa pruriginosa (EBP) is a form of dystrophic EB associated with severe pruritus and has skewed Th2 inflammation. Our study suggests that JAK inhibitors may offer superior efficacy compared to dupilumab in treating EBP. Moreover, JAK inhibitors downregulate JAK-STAT signalling and Th1/2 cell differentiation in lesional skin while not in peripheral blood.","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 5","pages":"e445"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442062/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-world experience of using dupilumab and JAK inhibitors to manage pruritus in epidermolysis bullosa pruriginosa.\",\"authors\":\"Ping-Chen Hou, Wilson Aala, Wei-Ting Tu, John A McGrath, Chao-Kai Hsu\",\"doi\":\"10.1002/ski2.445\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Epidermolysis bullosa pruriginosa (EBP) is a form of dystrophic EB associated with severe pruritus and has skewed Th2 inflammation. Our study suggests that JAK inhibitors may offer superior efficacy compared to dupilumab in treating EBP. Moreover, JAK inhibitors downregulate JAK-STAT signalling and Th1/2 cell differentiation in lesional skin while not in peripheral blood.\",\"PeriodicalId\":74804,\"journal\":{\"name\":\"Skin health and disease\",\"volume\":\"4 5\",\"pages\":\"e445\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442062/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin health and disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/ski2.445\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin health and disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/ski2.445","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

瘙痒性表皮松解症（EBP）是一种伴有严重瘙痒的营养不良性EB，具有偏向Th2的炎症反应。我们的研究表明，JAK抑制剂治疗EBP的疗效可能优于杜匹单抗。此外，JAK抑制剂能下调病变皮肤中的JAK-STAT信号传导和Th1/2细胞分化，而在外周血中则不能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-world experience of using dupilumab and JAK inhibitors to manage pruritus in epidermolysis bullosa pruriginosa.

Epidermolysis bullosa pruriginosa (EBP) is a form of dystrophic EB associated with severe pruritus and has skewed Th2 inflammation. Our study suggests that JAK inhibitors may offer superior efficacy compared to dupilumab in treating EBP. Moreover, JAK inhibitors downregulate JAK-STAT signalling and Th1/2 cell differentiation in lesional skin while not in peripheral blood.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Skin health and disease

CiteScore

1.70

自引率

0.00%

发文量

审稿时长

10 weeks